Kits Eyecare Valuation

Is 0P3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0P3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0P3 (€6.45) is trading below our estimate of fair value (€17.3)

Significantly Below Fair Value: 0P3 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0P3?

Other financial metrics that can be useful for relative valuation.

0P3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA194x
PEG Ratio17.8x

Price to Sales Ratio vs Peers

How does 0P3's PS Ratio compare to its peers?

The above table shows the PS ratio for 0P3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
MRX Mister Spex
0.3x2.2%€75.3m
BIKE Bike24 Holding
0.2x7.5%€54.3m
ART Artnet
1.6xn/a€36.5m
DOU Douglas
0.5x6.2%€2.1b
0P3 Kits Eyecare
2.3x19.0%€320.7m

Price-To-Sales vs Peers: 0P3 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (0.7x).


Price to Earnings Ratio vs Industry

How does 0P3's PE Ratio compare vs other companies in the DE Specialty Retail Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 0P3 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the European Specialty Retail industry average (0.4x).


Price to Sales Ratio vs Fair Ratio

What is 0P3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0P3 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: 0P3 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0P3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.25
€9.94
+59.1%
7.6%€11.38€9.03n/a7
Oct ’25€6.65
€9.90
+48.9%
7.8%€11.38€9.04n/a7
Sep ’25€7.20
€9.21
+27.9%
6.6%€10.04€8.03n/a6
Aug ’25€6.55
€7.16
+9.3%
10.2%€7.99€5.99n/a6
Jul ’25€5.70
€6.71
+17.7%
9.8%€7.79€6.10n/a5
Jun ’25€4.18
€6.47
+54.8%
9.9%€7.46€5.59n/a6
May ’25€3.78
€6.33
+67.4%
11.9%€7.49€5.45n/a6
Apr ’25€4.16
€6.31
+51.6%
11.9%€7.47€5.43n/a6
Mar ’25€4.42
€5.79
+31.0%
9.0%€6.81€5.45n/a6
Feb ’25€4.08
€5.85
+43.3%
9.3%€6.80€5.44n/a5
Jan ’25€4.16
€5.62
+35.0%
5.2%€6.13€5.45n/a4
Dec ’24€3.46
€5.64
+63.0%
5.7%€6.09€5.41n/a3
Nov ’24€3.30
€5.67
+71.8%
5.7%€6.12€5.44n/a3
Oct ’24€3.42
€5.67
+65.8%
5.7%€6.12€5.44€6.653
Sep ’24€3.36
€5.67
+68.8%
5.7%€6.12€5.44€7.203
Aug ’24€3.52
€4.96
+40.9%
6.4%€5.41€4.73€6.553
Jul ’24€3.08
€4.88
+58.4%
8.7%€5.45€4.43€5.703
Jun ’24€3.10
€4.88
+57.4%
8.7%€5.45€4.43€4.183
May ’24€3.22
€4.47
+38.8%
15.3%€5.43€3.90€3.783
Apr ’24€2.90
€4.46
+54.2%
15.3%€5.42€3.90€4.163
Mar ’24n/a
€3.54
0%
17.1%€4.14€2.93€4.422
Feb ’24n/a
€3.54
0%
17.1%€4.14€2.93€4.082
Jan ’24n/a
€3.77
0%
20.0%€4.52€3.02€4.162
Dec ’23n/a
€3.77
0%
20.0%€4.52€3.02€3.462
Nov ’23n/a
€3.77
0%
20.0%€4.52€3.02€3.302
Oct ’23n/a
€3.77
0%
20.0%€4.52€3.02€3.422

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies